0.05Open0.05Pre Close0 Volume319 Open Interest2.50Strike Price0.00Turnover140.91%IV50.00%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1800Delta0.4397Gamma34.00Leverage Ratio-0.0035Theta0.0002Rho6.12Eff Leverage0.0011Vega
InterCure Stock Discussion
Dow Jones· 1 min ago
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
PR Newswire
NEW YORK and HERZLIYA, Israel, Dec. 20, 2024
NEWS
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
InterCure achieved annual revenue of NIS 356 million and adjusted EBITDA of NIS 61 million, representing 17% of revenues.
The company maintained profitability for the fourteenth and fifteenth consecutive quarters despite challenges.
InterCure continues to expand its product portfolio and dedicated medical cannabis pharmacy chain.
The company is entitled to full compensat...
No comment yet